<DOC>
	<DOCNO>NCT02983097</DOCNO>
	<brief_summary>The goal study evaluate efficacy safety combination lenalidomide , immunomodulatory drug ( IMiD ) standard immunochemotherapy treatment , call R-DHAP . R-DHAP consist monoclonal antibody call Rituximab chemotherapy consist Dexamethasone , high dose Cytarabine , often call Ara-C , platinum base chemotherapy , either cisplatinum , , treatment cisplatinum contraindicate , carboplatinum .</brief_summary>
	<brief_title>Therapy Non-Hodgkin-Lymphoma Combination Lenalidomide + Rituximab , Dexa , High-dose ARA-C CisP</brief_title>
	<detailed_description>This phase 1/2 study evaluate efficacy safety lenalidomide add standard chemotherapy regime R-DHAP ( Rituximab , Dexamethasone , high-dose Cytarabine , Cis/Carboplatinum ) treatment relapsed refractory high-grade B-cell non-hodgkin-lymphoma ( NHL ) . The study hypothesis combination lenalidomide standard immunochemotherapy lead overall response rate least 60 % . In study , 3 round immunochemotherapy combination lenalidomide administer . After first second round therapy , peripheral hematopoetic stem cell harvest . Consolidation treatment autologous allogenic peripheral blood stem cell transplantation recommend patient suitable , part study . In phase 1 , six cohort least 6 patient treat study therapy , lenalidomide increase dosage , determine maximum tolerate dose ( MTD ) . In phase 2 , 50 patient treated MTD . Efficacy safety evaluate .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age : 1870 Risk group : All risk group histology : diagnosis recurrent primary progressive aggressive bcell nonhodgkin lymphoma , particular follicular lymphoma grade III diffuse large bcell lymphoma burkitt lymphoma mantle cell lymphoma , blastoid variant aggressive marginal zone lymphoma Performance status : ECOG 02 Criteria woman childbearing potential : Women childbearing potential : understand teratogenic risk associate study therapy , especially lenalidomide understand need reliable , uninterrupted birth control 4 week prior start study drug , duration study treatment , 4 week completion study treatment , able reliably use birth control , except patient commits absolute sexual abstinence , confirm monthly basis The following effective method contraception : implant levonorgestrelreleasing intrauterine system ( IUS ) medroxyprogesterone acetate depot tubal sterilisation sexual intercourse vasectomise male partner , vasectomy must confirm two negative semen analyse ovulationinhibitory progesteroneonly pills If establish effective contraception , female subject must refer appropriately trained health care professional contraceptive advice order contraception initiate . Understand even amenorrhea , must follow advice effective contraception Understand potential consequence pregnancy need rapidly consult risk pregnancy . Agree medically supervise pregnancy test minimum sensitivity 25 mIU/ml day study visit 3 day prior study visit subject effective contraception least 4 week . This requirement also apply woman childbearing potential practice complete continue abstinence . The test ensure subject pregnant start treatment . Agree medically supervise pregnancy test every 4 week include 4 week end study treatment , except case confirm tubal sterilization . These pregnancy test perform day study visit 3 day prior study visit . This requirement also apply woman childbearing potential practice complete continue abstinence . Male patient : Agree use condom throughout study drug therapy , dose interruption one week cessation study therapy partner childbearing potential contraception . Agree donate semen study drug therapy one week end study drug therapy . All patient : Agree abstain donate blood take study drug therapy one week follow discontinuation study drug therapy . Agree share study medication another person return unused study drug investigator Patients must able take low molecular weight heparin prophylactic anticoagulation Written inform consent necessary pregnant lactating female already initiate salvage lymphoma therapy ( except prephase specify study ) serious accompany disorder impair organ function cause significant clinical problem reduce lyfe expectancy , particular : heart : angina pectoris CCS &gt; 2 cardiac failure NYHA &gt; 2 and/or EF &lt; 45 % lung : FeV1 &lt; 60 % , diffusion capacity &lt; 50 % reference value kidney : creatinine &gt; 2 time upper reference limit liver : bilirubin &gt; 2 time upper reference limit platelet &lt; 80000/mm³ , leukocytes &lt; 2500/³ CNS involvement lymphoma know hypersensitivity medication use know HIVpositivity suspicion patient compliance poor , especially rule effective contraception follow simultaneous participation treatment study nonconformity eligibility criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>lymphoma</keyword>
	<keyword>relapse</keyword>
	<keyword>recurrence</keyword>
	<keyword>progress</keyword>
	<keyword>progressive</keyword>
	<keyword>b-cell lymphoma</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>IMiD</keyword>
	<keyword>Salvage chemotherapy</keyword>
	<keyword>peripheral stem cell mobilization</keyword>
	<keyword>lenalidomide</keyword>
	<keyword>Rituximab</keyword>
	<keyword>CD20</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>platinum-based chemotherapy</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Cisplatinum</keyword>
	<keyword>Carboplatinum</keyword>
	<keyword>Dexamethasone</keyword>
</DOC>